Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DoJ joins off-label suit against J&J

Executive Summary

The Department of Justice has intervened in two whistleblower suits claiming Scios and parent Johnson & Johnson marketed Natrecor (nesiritide) for off-label use. The drug was approved in 2001 for treatment of acute heart failure and DoJ says Scios shortly thereafter began an aggressive campaign marketing it for scheduled, serial outpatient infusions for patients with less severe heart failure. J&J acquired Scios in 2003. Former Scios sales managers filed separate False Claim Act suits against Scios and J&J in the Northern District of California
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS050719

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel